PRECLINICAL STUDY

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence

Sara Jansson1 · Kristina Aaltonen1 · Pär-Ola Bendahl1 · Anna-Karin Falck2 · Maria Karlsson3 · Kristian Pietras4 · Lisa Rydén3,5

Received: 23 August 2017 / Accepted: 5 January 2018 / Published online: 29 January 2018 © The Author(s) 2018. This article is an open access publication

Abstract

Purpose The platelet-derived growth factor (PDGF) signalling pathway is often dysregulated in cancer and PDGF-receptor expression has been linked to unfavourable prognostic factors in breast cancer (e.g. ER negativity, high Ki67 and high grade). This study aimed to evaluate the expression of PDGFRα, PDGFRβ and ligand PDGF-CC in breast cancer in relation to molecular subtypes and prognosis.

Methods Protein expression of tumour and/or stromal cell PDGFRα, PDGFRβ and PDGF-CC was evaluated in primary tumours (N = 489), synchronous lymph node metastases (N = 135) and asynchronous recurrences (N = 39) using immunohistochemistry in a prospectively maintained cohort of primary breast cancer patients included during 1999–2003. Distant recurrence-free interval (DRFi) was the primary end-point.

Results High expression of all investigated PDGF family members correlated to increasing Nottingham histopathological grade and high Ki67. Tumour cells displayed high expression of PDGFRα in 20%, and PDGF-CC in 21% of primary tumours, which correlated with the triple-negative subtype (TNBC). Patients with high PDGF-CC had inferior prognosis (P = 0.04) in terms of 5-year DRFi, whereas PDGFRα was up-regulated in lymph node metastasis and recurrences compared to primary tumours. High primary tumour PDGFRα was associated with increased risk of central nervous system (CNS) recurrence.

Conclusions High PDGFRα and PDGF-CC expression were linked to breast cancer with an aggressive biological phenotype, e.g. the TNBC subtype, and high PDGF-CC increased the risk of 5-year distant recurrence. Tumour cell PDGFRα was significantly up-regulated in lymph node metastases and asynchronous recurrences. Our findings support an active role of the PDGF signalling pathway in tumour progression.

Keywords Breast cancer · Triple-negative breast cancer · Platelet-derived growth factor receptor · Platelet-derived growth factor-CC · Tyrosine kinase receptor · Targeted therapy

Introduction

The platelet-derived growth factor receptor (PDGFR) pathway is a signalling network of importance for the normal development of cells of mesenchymal origin. The PDGF signalling network consists of two tyrosine kinase receptors,
PDGFR alpha (PDGFRα) and PDGFR beta (PDGFRβ), and five ligands PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD, which are formed from four gene products (PDGF A, B, C and D) [1]. Autocrine stimulation of the pathway is frequently observed in various neoplasms, such as gliomas [2], gastro-intestinal stromal tumours (GISTs) [3] and chronic myelomonocytic leukaemia [4]. In addition, dysregulation of paracrine PDGFR signalling can cause extracellular matrix remodelling in a tumour-promoting way to facilitate migration, invasion, angiogenesis and possibly also lymph angiogenesis [5, 6].

In breast cancer, most studies of the PDGF signalling pathway examine the expression of PDGFRα and PDGFRβ. PDGFRα expression has been described both in stroma and in tumour cells. High tumour cell PDGFRα expression has been linked to lymph node metastasis, human epidermal growth factor receptor 2 (HER2) positivity [7], high histologic grade, oestrogen receptor (ER) negativity, progesterone receptor (PR) negativity and the triple-negative breast cancer subtype (TNBC) [8, 9]. High stromal PDGFRα has been linked to HER2 positivity and high Ki67 [9]. PDGFRβ expression in breast cancer has only been reported in stroma and high expression has been associated to HER2 positivity, high Ki67 [9], high histopathologic grade, ER negativity and shorter survival [10].

The PDGF-CC ligand was discovered towards the end of the 1990s and it has been shown to be involved in tumour growth by paracrine signalling through PDGFRα in malignant melanoma and cervical carcinoma [11, 12]. However, to date little is known about the role of PDGF-CC in breast cancer. We have recently shown that tumour cell-derived PDGF-CC acts on neighbouring tumour stromal cells in mouse models, and we proposed that the PDGF signalling pathway is a regulator of breast tumour subtype with high PDGF-CC driving breast tumours towards a more basal-like phenotype [13]. Basal-like breast cancer (BLBC) is a subtype of breast cancer defined by gene expression profiling and it is characterised by the expression of genes related to basal epithelial cells such as keratin 5, keratin 17, integrin-β4 and laminin [14]. BLBC largely overlaps with the molecular surrogate breast cancer subtype TNBC, which is defined by immunohistochemistry as being negative for the ER, PR and HER2 receptors [15]. Patients with TNBC are generally younger, have larger tumours with high grade at diagnosis and are more frequently BRCA-mutation carriers [16]. They also have a poor prognosis and no targeted therapies are hitherto available. It is thus particularly desirable to find targetable tumour-driving pathways within TNBC [17]. The PDGF signalling network holds promise of such a pathway, in TNBC in particular and in breast cancer in general.

The aim of the present study was to explore the expression of PDGFRα, PDGFRβ and ligand PDGF-CC in breast cancer to elucidate if these proteins are associated with molecular surrogate subtypes, type of metastatic location and prognosis in breast cancer. A secondary aim was to explore the relation to tumour progression by investigating changes in protein expression between primary tumour, synchronous lymph node metastases and asynchronous recurrences.

Materials and methods

Patients

The patient cohort in this study was originally assembled for a prospective observational study with the aim of evaluating the presence and prognostic value of disseminated tumour cells in the bone marrow of patients diagnosed with primary breast cancer [18]. The study was approved by the Lund University ethics committee, and a written informed consent was obtained from all the included patients (LU699-09, LU75-02). Further information about the patient cohort has been published elsewhere [8, 18–20]. Detailed information on routine prognostic factors, St Gallen molecular subtype and clinical follow-up data were assembled for all the patients as described by Falck et al. [19, 20]. The latest review of patient charts to evaluate recurrence status was performed in 2015 and all events until November 2015 were recorded. A recurrence was defined as a radiologic and/or biopsy verified breast cancer-related event. Recurrences within the breast, chest wall, axilla or loco-regional lymph nodes were considered as loco-regional, whereas recurrences in distant organs [e.g. liver, lung and central nervous system (CNS)] were considered as distant. Data on breast cancer-related death were retrieved from the Swedish Register of Causes of Death (Central Statistics Office). We followed the REPorting recommendations for tumour MARKer prognostic studies (REMARK) criteria [21].

Tissue microarray and immunohistochemistry

Tissue microarrays (TMAs) of formalin-fixed, paraffin-embedded tumour tissue samples were retrieved from the Department of Pathology, in Lund and Helsingborg, Sweden. TMAs consisted of tissue core biopsies of 1.0 mm in diameter taken from representative areas of invasive breast cancer using a tissue array machine (TMArayer™, Pathology Devices, Inc.). Two core biopsies were taken from each tumour sample. TMA sections between 3 and 4 μm thick were transferred to glass slides (Menzel Super frost plus, Thermo Scientific, Germany), dried at room temperature and baked in a heat chamber for 2 h at 60 °C. After deparaffinisation and antigen retrieval, immunohistochemistry (IHC) staining was performed using Autostainer Plus
EGFR and CK5/6 have been described in detail elsewhere.

Staining procedures and assessments of ER, PR, HER2, (intermediate, low or absent expression) as described above. dichotomized into positive (high expression) versus negative CC expression was analysed both as ordinal variables, and the two cores was used. PDGFRα, PDGFRβ and PDGF-CC expression were assessed by a clinical pathologist (DG) and scored for a tumour was considered positive staining intensity 0–3 (0 = negative, 1 = weak, 2 = intermediate, low or absent expression) if the intensity was 0–2 [10].

For both tumour cell and stromal cell staining, only TMA core biopsies with > 100 invasive tumour cells were included. In the statistical analyses, the highest value for the two cores was used. PDGFRα, PDGFRβ and PDGF-CC expression was analysed both as ordinal variables, and dichotomized into positive (high expression) versus negative (intermediate, low or absent expression) as described above. Staining procedures and assessments of ER, PR, HER2, EGFR and CK5/6 have been described in detail elsewhere [19].

Statistical analysis

The association between biomarker expression and different patient and tumour characteristics was analysed with binary logistic regression. Fisher’s exact test was used to explore any association between primary tumour PDGF expression (positive or negative) and site of recurrence. Comparison of biomarker status between primary tumours, lymph node metastases and distant recurrences was performed using the McNemar test. The Jonckheere Terpstra test was used to test for ordered differences between receptor and ligand status. To evaluate survival effect, Kaplan–Meier survival curves and log rank test or log rank linear trends for factor levels were used. Hazard ratios (HR) were calculated by Cox regression and multivariable analyses were adjusted for age, tumour size, synchronous lymph node metastasis, Nottingham histological grade (NHG) and subtype according to St Gallen 2013. Distant recurrence-free interval (DRFi) was used as end-point. DRFi was defined as the time from surgery of the primary tumour until radiologic and/or biopsy verified distant recurrence or breast cancer-related death. Patients without event were censored at last medical follow-up visit. DRFi was stratified into three time intervals (0–5 years, > 5–10 years and > 10 years) which were analysed separately to explore short- and long-term effects of the biomarkers, respectively. The results from these post hoc analyses should be interpreted cautiously. Statistical calculations were performed using IBM SPSS Statistics (version 24.0, IBM, Armonk, NY, USA). All P values presented are two-sided and P values < 0.05 were considered statistically significant.

Results

Patient and tumour characteristics

A total of 550 patients were included in the present study. Primary tumours from 473 patients (86%) had a known St Gallen subtype according to guidelines from 2013 [15] (Luminal A = 193; Luminal B HER2− = 153; Luminal B HER2+ = 79; HER2+ = 15; triple-negative breast cancer [TNBC] = 33). Further data on patient and tumour characteristics are provided in Table 1. Median age at diagnosis was 57.8 years (26–91 years) and median follow-up time for patients alive without any event was 13.7 years (1.0–16.6 years). Synchronous lymph node metastases were present in 215 patients and asynchronous recurrence was recorded in 153 patients. Amongst the asynchronous recurrences, 76 patients had a local, loco-regional or contralateral event and 77 patients developed distant recurrence. Eighty-nine patients experienced early recurrence (within 5 years of primary breast cancer diagnosis). Due to limited remaining tissue material, synchronous lymph node metastasis and asynchronous recurrences were only evaluable in 135 and 39 patients, respectively (Fig. 1).

Patient and tumour characteristics in relation to primary tumour expression of PDGFRα, PDGFRβ and PDGF-CC

Examples of IHC staining are given in Fig. 2. Tumour cells showed high expression of PDGFRα in 100 (20%) and PDGF-CC in 103 (21%) of the evaluated primary tumours. Stromal cells showed high expression of PDGFRα in 243 (50%) and PDGFRβ in 128 (27%) of the evaluated primary tumours. High expression of all investigated PDGF family members correlated to increasing NHG and high Ki67, and also to different degrees to TNBC, expression of cytokertatin 5/6 (CK5/6+), young age (< 50 years), large tumour size, ER−, PR− and EGFR+ (Table 1).
Table 1 Odds ratio (OR) of biomarker expression in relation to tumour and patient characteristics

| Biomarker expression | All patients | PDGFRα in tumour cells OR (95% CI) | PDGFRα in stroma OR (95% CI) | PDGFRβ in stroma OR (95% CI) | PDGF-CC in tumour cells OR (95% CI) |
|----------------------|--------------|-----------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| **Age (median)**     |              |                                   |                               |                               |                                     |
| < 50                 | 110 (20%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| ≥ 50                 | 440 (80%)    | 0.80 (0.47–1.35)                   | 0.46 (0.29–0.73)*             | 0.56 (0.35–0.89)*             | 0.33 (0.21–0.55)*                   |
| **T-size**           |              |                                   |                               |                               |                                     |
| ≤ 20 mm              | 366 (67%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| > 20 mm              | 179 (33%)    | 0.86 (0.54–1.38)                   | 0.97 (0.66–1.40)              | 1.08 (0.71–1.66)              | 2.14 (1.37–3.35)*                   |
| **Node status**      |              |                                   |                               |                               |                                     |
| No                   | 319 (60%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| N+                   | 215 (40%)    | 0.67 (0.42–1.06)                   | 1.23 (0.85–1.77)              | 1.21 (0.80–1.82)              | 1.10 (0.70–1.71)                     |
| **NHG**              |              |                                   |                               |                               |                                     |
| I                    | 118 (22%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| II                   | 287 (54%)    | 0.99 (0.54–1.80)                   | 1.08 (0.68–1.72)              | 1.41 (0.80–2.51)              | 1.26 (0.63–2.54)                     |
| III                  | 129 (24%)    | 1.94 (1.03–3.69)*                 | 3.01 (1.74–5.21)*             | 2.55 (1.37–4.73)*             | 7.72 (2.83–11.52)*                  |
| **Ki67**             |              |                                   |                               |                               |                                     |
| Low (<20)            | 335 (67%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| High (>20)           | 165 (33%)    | 3.47 (2.20–5.48)*                 | 1.82 (1.23–2.67)*             | 2.12 (1.39–3.23)*             | 5.13 (3.21–8.20)*                   |
| **St Gallen subtype**|             |                                   |                               |                               |                                     |
| Luminal A            | 193 (41%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Luminal B HER2−      | 153 (32%)    | 1.74 (1.01–3.00)*                 | 1.07 (0.70–1.66)              | 1.03 (0.63–1.70)              | 3.60 (1.84–7.04)*                   |
| Luminal B HER2+      | 79 (17%)     | 1.38 (0.70–2.71)                   | 1.58 (0.92–2.71)              | 1.40 (0.78–2.52)              | 3.34 (1.55–7.19)*                   |
| HER2-type            | 15 (3%)      | 0.90 (0.19–4.25)                   | 6.68 (1.44–30.97)*            | 0.84 (0.22–3.19)              | 10.10 (2.99–34.19)*                 |
| TNBC                 | 33 (7%)      | 2.71 (1.19–6.18)*                 | 1.65 (0.78–3.48)              | 0.94 (0.39–2.23)              | 30.12 (11.72–77.43)*                |
| **ER**               |              |                                   |                               |                               |                                     |
| Neg                  | 57 (11%)     | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Pos                  | 449 (89%)    | 0.82 (0.42–1.58)                   | 0.41 (0.22–0.75)*             | 1.06 (0.56–2.03)              | 0.10 (0.06–0.19)*                   |
| **PR**               |              |                                   |                               |                               |                                     |
| Neg                  | 108 (23%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Pos                  | 367 (77%)    | 0.77 (0.46–1.30)                   | 0.75 (0.49–1.16)              | 0.93 (0.57–1.51)              | 0.18 (0.11–0.29)*                   |
| **EGFR**             |              |                                   |                               |                               |                                     |
| Neg                  | 419 (83%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Pos                  | 84 (17%)     | 1.25 (0.71–2.21)                   | 1.98 (1.21–3.22)*             | 1.49 (0.89–2.49)              | 5.97 (3.56–10.01)*                  |
| **CK5/6**            |              |                                   |                               |                               |                                     |
| Neg                  | 378 (75%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Pos                  | 124 (25%)    | 1.65 (1.02–2.68)*                 | 1.31 (0.87–2.00)              | 1.00 (0.62–1.58)              | 3.67 (2.30–5.87)*                   |
| **HER2**             |              |                                   |                               |                               |                                     |
| Neg                  | 440 (88%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Pos                  | 62 (12%)     | 0.86 (0.49–1.51)                   | 1.90 (1.20–3.00)*             | 1.42 (0.88–2.32)              | 1.52 (0.91–2.53)                     |
| **Recurrence**       |              |                                   |                               |                               |                                     |
| No                   | 398 (72%)    | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Loco-regional or contralateral | 75 (14%) | 1.22 (0.65–2.31) | 1.80 (1.03–3.16)* | 1.10 (0.61–1.96) | 2.19 (1.23–3.91)* |
| Distant              | 77 (14%)     | 1.08 (0.58–2.02)                   | 0.76 (0.40–1.46)              | 0.82 (0.45–1.50)              | 1.01 (0.53–1.92)                     |
| **Metastatic location** |         |                                   |                               |                               |                                     |
| Bone                 | 28 (36%)     | 1.0                               | 1.0                           | 1.0                           | 1.0                                 |
| Visceral             | 43 (56%)     | 1.22 (0.32–4.65)                   | 0.52 (0.19–1.42)              | 0.84 (0.27–2.64)              | 0.74 (0.20–2.74)                     |
| CNS                  | 6 (8%)       | 11.50 (1.55–85.15)*               | 0.54 (0.08–3.45)              | 0                             | 4.2 (0.65–27.36)                     |

* Significant at the 0.05 level

NHG Nottingham histological grade, ER oestrogen receptor, PR progesterone receptor, EGFR epidermal growth factor receptor; CK5/6 cytokeratin 5/6, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, CNS central nervous system
The 77 patients that developed distant recurrence were divided into three groups based on the primary distant metastatic site; bone only (28 patients), visceral (43 patients) and CNS (6 patients) (Fig. 3a). If several primary metastatic locations were present, the worst was recorded in the following order: 1: CNS, 2: visceral and 3: bone. The relation between primary tumour PDGF expression and site of distant recurrence is given in Fig. 3b. Recurrence within CNS was more common in patients with high primary tumour cell PDGFRα expression, 4/15 (27%) versus 2/58 (3%), \( P = 0.01 \).

**Biomarker expression and tumour progression**

Figure 1 presents an overview of the PDGF assessments at different locations. Tumour cells showed high expression of PDGFRα in 76 (56%) and PDGF-CC in 29 (22%) of synchronous lymph node metastases, whereas stromal cells showed high expression of PDGFRα in 68 (50%) and PDGFRβ in 46 (34%). In asynchronous recurrences, tumour cells showed high expression of PDGFRα in 23 (64%) and PDGF-CC in 8 (21%). Stromal cells showed high expression of PDGFRα in 11 (31%) and PDGFRβ in 2 (5%) of evaluated asynchronous recurrences.

A substantial number of tumours displayed a shift in biomarker expression from primary tumour to lymph node metastases and recurrences. The shift was significantly skewed for PDGFRα expression in tumour cells, which was up-regulated in lymph node metastases and recurrences, and for stromal PDGFRβ expression, which was down-regulated in recurrences (Table 2).

**Concomitant expression of ligand PDGF-CC and the PDGF receptors**

In total, 80 primary tumours (18%) had concomitant high expression of ligand PDGF-CC in tumour cells and at least one of the PDGF receptors in tumour and/or stromal cells. Forty-one (8%) of primary tumours displayed a high expression of both PDGFRα in tumour cells and PDGF-CC, 63 (13%) of PDGFRα in stromal cells and PDGF-CC, and 36 (7%) of PDGFRβ in stromal cells and PDGF-CC. Only 2 tumours had high expression of PDGFRβ and PDGF-CC in combination with absent or low expression of PDGFRα (in both stromal and tumour cells), whereas 42 tumours had high expression of PDGFRα (in stromal and/or tumour cells) and PDGF-CC in combination with low PDGFRβ (Supplementary Table S1).
Forty-nine (10%) of primary tumours had high expression of PDGFRα in both stromal and tumour cells, whereas 182 (37%) had low or absent expression of this receptor in both stromal and tumour cells.

To further explore the relation between PDGF-CC and the PDGF receptors, we analysed receptor–ligand combinations using non-dichotomized data. This showed a significant association between increasing expression of both PDGFRα and PDGFRβ, and increasing PDGF-CC levels ($P < 0.001$ for tumour and stromal cell PDGFRα expression, $P = 0.004$ for stromal cell PDGFRβ expression, Supplementary Fig. S1a–c).

All combinations of concomitant high expression of ligand PDGF-CC and either of the PDGF receptors were significantly associated with young age, increasing NHG, high Ki67, TNBC, ER−, PR−, CK5/6+ and EGFR+ (Supplementary Table S2). No significant difference was seen in survival for patients carrying tumours with concomitant high receptor and ligand expression (data not shown).

Primary tumour biomarker expression and prognosis

One hundred and eleven patients (20%) experienced distant breast cancer recurrence and/or breast cancer-related death and contributed to events in DRFi. Kaplan–Meier and log rank test showed a significant difference in DRFi over different breast cancer subtypes (Fig. 4a, $P < 0.001$). As expected, Luminal A had the best prognosis and TNBC the worst.

For patients with primary tumours positive versus negative for PDGF-CC, no significant difference in DRFi was found over the complete follow-up time (Fig. 4b, $P = 0.30$). However, the survival curve indicated a prognostic effect over the first few years following breast cancer diagnosis. We thus divided the follow-up time into three intervals, 0–5 years, > 5–10 years and > 10 years. This revealed a significant increased risk of early breast cancer event (recurrence or breast cancer-related death within 5 years of primary diagnosis) in the group of patients with tumours
Fig. 3  a Overview of primary metastatic site at time of recurrence. b Relation between primary tumour PDGF expression (receptors α, β or ligand –CC) and site of distant recurrence.

Table 2 Biomarker concordance and discordance in matched pairs of primary tumours versus corresponding lymph node metastases and asynchronous recurrences

| Biomarker expression | PDGFα in tumour cells | PDGFα in stroma | PDGFβ in stroma | PDGF-CC in tumour cells |
|----------------------|-----------------------|-----------------|-----------------|------------------------|
|                      | Location              | N (%)           | P*              | N (%)           | P*              | N (%)           | P*              |
| PT versus N          |                       |                 |                 |                 |                 |                 |                 |
| PT pos/N pos         | 11 (8)                | < 0.001         | 41 (32)         | 0.7             | 17 (14)         | 0.4             | 18 (14)         | 0.2             |
| PT pos/N neg         | 6 (5)                 |                 | 29 (22)         |                 | 20 (26)         |                 | 16 (13)         |                 |
| PT neg/N pos         | 61 (47)               |                 | 25 (19)         |                 | 27 (21)         |                 | 8 (6)           |                 |
| PT neg/N neg         | 52 (40)               |                 | 35 (27)         |                 | 62 (49)         |                 | 86 (67)         |                 |
| Total                | 130 (100)             |                 | 130 (100)       |                 | 126 (100)       |                 | 128 (100)       |                 |
| PT versus R          |                       |                 |                 |                 |                 |                 |                 |                 |
| PT pos/R pos         | 9 (26)                | 0.02            | 2 (6)           | 0.6             | 0 (0)           | 0.02            | 6 (17)          | 0.07            |
| PT pos/R neg         | 3 (9)                 |                 | 11 (32)         |                 | 9 (24)          |                 | 9 (26)          |                 |
| PT neg/R pos         | 13 (38)               |                 | 8 (24)          |                 | 1 (3)           |                 | 2 (6)           |                 |
| PT neg/R neg         | 9 (26)                |                 | 13 (38)         |                 | 27 (73)         |                 | 18 (51)         |                 |
| Total                | 34 (100)              |                 | 34 (100)        |                 | 37 (100)        |                 | 35 (100)        |                 |

PT primary tumour, N lymph node metastasis, R recurrence, neg negative, pos positive

*McNemar test
Fig. 4  a–c Kaplan–Meier survival curves showing DRFi (years) in relation to St Gallen molecular subtypes (a), expression of PDGF-CC in tumour cells dichotomized into positive versus negative (b), and staining intensity of PDGF-CC ranging from 0 (negative) to 3 (strong) (c). $P$ values from log rank test and log rank linear trends for factor levels.

a  St Gallen subtypes

| Subtype           | At risk | Follow-up, years |
|-------------------|---------|------------------|
| TNBC              | 33      | 0 5 10 15        |
| HER2+/non-Lum     | 15      | 3 12 52 197      |
| Lum B/HER2+       | 79      | 125 52 8 3      |
| Lum B/HER2−       | 153     | 125 107 19 3    |
| Lum A             | 193     | 178 156 31 35    |

b  PDGF-CC in tumour cells

| Expression       | At risk | Follow-up, years |
|------------------|---------|------------------|
| Positive         | 103     | 80 72 23 23       |
| Negative         | 380     | 329 278 47 47     |

c  PDGF-CC in tumour cells

| Staining Intensity | At risk | Follow-up, years |
|--------------------|---------|------------------|
| Strong             | 163     | 80 72 23 23       |
| Intermediate       | 185     | 160 138 29 29     |
| Weak               | 175     | 151 126 17 17     |
| Negative           | 20      | 18 14 1 1        |

$P$ values from log rank test and log rank linear trends for factor levels.
positive for PDGF-CC [Fig. 4b, HR 1.77 (95% confidence interval (CI) 1.03–3.04), \(P = 0.04\)]. This increase did not remain significant in multivariable analysis adjusted for age, tumour size, node status, NHG and St Gallen molecular subtype (HR 1.14; 95% CI 0.59–2.19) (Supplementary Table S3). For the late events (occurring after 10 years), there was an increased risk amongst patients with tumours negative for PDGF-CC.

We also analysed the intensity of PDGF-CC expression (0–3) and found a trend towards a worse prognosis with increasing expression of PDGF-CC over the whole time interval and a significantly worse prognosis during the first 5 years (Fig. 4c, log rank linear trends for factor levels \(P = 0.1\) and \(P = 0.02\), respectively).

Analysis of DRFi in relation to PDGF-receptor expression showed no difference in prognosis for patients with tumours positive versus negative for PDGFRα or PDGFRβ over the whole follow-up period (Supplementary Fig. S2a–c).

**Discussion**

We present novel data on expression of PDGFRα, PDGFRβ and ligand PDGF-CC in primary breast tumours, synchronous lymph node metastasis and asynchronous recurrences in relation to St Gallen Molecular subtypes and long-term follow-up data in a large cohort of primary breast cancer patients. Data are accumulating on the importance of the PDGF receptors α and β in breast cancer, but the presented results have been conflicting and not related to modern pathology. Furthermore, little is known concerning the role of ligand PDGF-CC. We found that high expression of the investigated members of the PDGF family correlated to several prognostic patient and tumour characteristics that indicate tumours’ inherent biological aggressiveness (e.g. younger age, increasing NHG, high Ki67 and negative ER and PR). This is in line with what has been reported in some previous studies [9, 10] but it contrasts with Weigel et al. who found no significant correlations between PDGFR and the expression of established prognostic biomarkers. Reasons for diverging data could be the use of different antibodies, different inclusion criteria and the location of marker expression.

Interestingly, we report for the first time a significant up-regulation of tumour cell PDGFRα expression in lymph node metastasis and asynchronous recurrences, as a sign of its role in tumour progression. Moreover, we found a significantly increased risk of early breast cancer recurrence amongst patients with tumours expressing increasing levels of PDGF-CC. This effect was visualised by the Kaplan–Meier survival curves which indicate that the prognosis is related to the level of PDGF-CC expression (Fig. 4c). Up-regulation of members of the PDGF signalling pathway has previously been shown to occur during epithelial-to-mesenchymal transition in in vitro/in vivo cellular models [22], and subsequent experiments in mouse tumour models present support that an autocrine PDGF/PDGFR loop contribute to tumour progression and metastasis in vivo [23]. These studies conclude that PDGFR signalling plays an essential role during cancer progression, as has also been observed in our findings.

Approximately 30% of women with primary breast cancer eventually experience distant breast cancer recurrence. We found that high expression of PDGFRα in tumour cells of the primary tumour was correlated to subsequent first distant recurrence occurring within CNS. Even if prognosis in metastatic breast cancer has improved over the past decades [24], metastasis within CNS is a major limitation of life quality and survival [25]. Deciphering the biology behind metastasis and target organs for metastatic spread is important in order to develop targeted therapies. In glioblastoma, autocrine signalling by PDGF-CC/PDGFRα has been proposed to have a role in tumour development and Lokker et al. detected concomitant expression of PDGF-CC and PDGFRα in 6/6 tested glioblastoma cell lines, and 5/5 investigated primary glioblastoma tissue samples [26]. Furthermore, PDGF-CC has been shown to increase the permeability of the blood–brain barrier (BBB) [27], and the role of the PDGFRα/PDGF-CC pathway relative to BBB dysfunction in neurological disorders was recently reviewed [28]. In our cohort, patients who developed CNS metastases had primary tumours with high expression of tumour cell PDGFRα in 67%, PDGF-CC in 50% and concomitant high ligand/receptor expression in 33% of cases, indicating an active role of the PDGF pathway in these tumours. Thus it is possible that the PDGF pathway is involved when a tumour cell crosses the BBB. The number of patients with CNS recurrence is small within this cohort but the finding is intriguing. Unfortunately, we had no tumour tissue available from CNS metastases to explore the expression of the PDGF members. However, Kim et al. recently investigated the expression of tumour cell PDGFRα in breast cancer CNS metastases and found high expression in 12/38 (32%) metastases [29]. Unfortunately, comparisons between these different studies are limited due to different antibodies and scoring systems for PDGFRα staining.

In this study we also explored concomitant expression of PDGFRα and PDGFRβ, and ligand PDGF-CC. Experiments in vitro have shown that PDGF-CC binds to and stimulates homodimers of PDGFRα, and heterodimers of PDGFRα and PDGFRβ, but not homodimers of PDGFRβ [30]. However, the binding capacity of PDGF-CC in vivo is not completely known and we thus explored all the three receptor/ligand combinations. Almost all tumours with high stromal cell PDGFRβ and high tumour cell PDGF-CC also had high PDGFRα, either in stromal or tumour cells. In contrast, more than half of the tumours with high
PDGF-CC and high PDGFRα expression in tumour or stromal cells displayed low PDGFRβ. These findings support that PDGF-CC binds to and signals through receptor combinations including the PDGFRα in vivo. Concomitant PDGFRα and PDGF-CC expression varied markedly over the molecular subtypes where the TNBC displayed co-expression in 59% of the tumours, whereas the luminal subtypes only displayed co-expression in 5% (Luminal A) to 19% (Luminal B HER2+). This adds further evidence to the involvement of the PDGF signalling pathway in TNBC as indicated in previous studies [8, 9, 13] and this pathway might thus be a target for therapy in this difficult-to-treat subgroup of breast cancer.

The strength of the present study is that it is performed in a large cohort of breast cancer patients with long follow-up time (13.7 years). The study enables analysis of the PDGF signalling pathway in tumour tissue biopsies from several locations where data on clinically important biomarkers and St Gallen molecular subtypes were available, which allows to evaluate the study results in relation to modern pathology. A limitation is that there was limited tissue material available from lymph node metastasis and recurrences. Also, we recorded distant recurrence and/or breast cancer-related death in only 20% of patients during the follow-up time diminishing the power of the study.

In conclusion, we show that high expression of PDGFRα, PDGFRβ and ligand PDGF-CC is associated to several important prognostic patient and tumour characteristics in breast cancer, indicating a link to tumours with inherent biological aggressiveness. Tumour cell expression of PDGFRα is commonly up-regulated in lymph node metastases and asynchronous recurrences, whereas high expression of PDGF-CC is related to early breast cancer recurrence supporting an active role of the PDGF signalling pathway in tumour progression. Furthermore, our results indicate an intriguing connection between the PDGF pathway and metastatic spread to the CNS, which merits further exploration. In summary, our data encourage further evaluation of the PDGF receptors and ligands in breast cancer, as well as of strategies to target this pathway since evidence is compiling for its involvement in breast cancer progression.

Acknowledgements This paper was supported by funds from the Swedish Breast Cancer Organization (BRO), The Swedish Cancer Society, The Gunnar Nilsson Cancer Foundation, The Mrs Berta Kamprad Foundation, Skåne County Council’s Research and Development Foundation, Governmental Funding of Clinical Research within the National Health Service (ALF), The Gyllenstiernska Krappurup Foundation and ERC Consolidator Grant. We would like to thank Kristina Lövgren for immunohistochemical staining and late Dr. Dorte Aamand Grabau, clinical pathologist, for immunohistochemical assessments. We also would like to thank Professor Ulf Eriksson and Professor Andrew M Scott for providing the PDGF-CC antibody.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Demoulin JB, Essaghir A (2014) PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 25(3):273–283. https://doi.org/10.1016/j.cytogfr.2014.03.003
2. Nazarenko I, Hede SM, He X, Hedren A, Thompson J, Lindstrom MS, Nister M (2012) PDGF and PDGFR receptors in glioma. Upsala J Med Sci 117(2):99–112. https://doi.org/10.3109/03009373.2012.665097
3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRα activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710. https://doi.org/10.1126/science.1079666
4. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77(2):307–316
5. Ehnman M, Ostman A (2014) Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin Investig Drugs 23(2):211–226. https://doi.org/10.1517/13543784.2014.847086
6. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312. https://doi.org/10.1101/gad.1653708
7. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7(5):R788–R795. https://doi.org/10.1186/bcr1304
8. Jansson S, Bendahl PO, Grabau DA, Falck AK, Ferno M, Aaltinen K, Ryden L (2014) The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRalpha, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One 9(7):e102176. https://doi.org/10.1371/journal.pone.0102176
9. Park SY, Kim HM, Koo JS (2015) Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 149(3):727–741. https://doi.org/10.1007/s10549-015-3291-9
10. Paulsson S, Joblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175(1):334–341. https://doi.org/10.2353/ajpath.2009.081030
11. Anderberg C, Li H, Fredriksen L, Andera J, Betsholtz C, Li X, Eriksson U, Pietras K (2009) Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Can Res 69(1):369–378. https://doi.org/10.1158/0008-5472.can-08-2724
12. Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5(1):e19. https://doi.org/10.1371/journal.pmed.0050019

13. Roswall P, Bocci M, Bartoshek M, Li H, Kristiansen G, Jansson S, Lehnn S, Sjolund J, Reid S, Larsson C, Erikksson P, Anderberg C, Cortez E, Saai LH, Orsmark-Pietras C, Cordero E, Kristian Haller B, Hakkinen J, Burvenich JG, Lim E, Oriomo A, Hoglund M, Rydén L, Moch H, Scott AM, Erikksson U, Pietras K (2018) Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling. Nat Med (in press)

14. Pietras K, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093

15. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart MJ, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. https://doi.org/10.1093/annonc/mdt303

16. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389

17. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) New strategies for triple-negative breast cancer—deciphering the heterogeneity. Clin Cancer Res 20(4):782–790. https://doi.org/10.1158/1078-0432.CCR-13-0583

18. Falck AK, Bendahl PO, Ingvar C, Isola J, Jonsson PE, Lindblom P, Lovgren K, Rennstam K, Ferno M, Ryden L (2012) Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer 12(1):403. https://doi.org/10.1186/1471-2407-12-403

19. Falck AK, Bendahl PO, Chebil G, Olsson H, Ferno M, Ryden L (2013) Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up. Breast Cancer Res Treat 140(1):93–104. https://doi.org/10.1007/s10549-013-2617-8

20. Falck AK, Rome A, Ferno M, Olsson H, Chebil G, Bendahl PO, Ryden L (2016) St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up. Br J Surg 103(5):513–523. https://doi.org/10.1002/bjs.10070

21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235. https://doi.org/10.1007/s10549-006-9242-8

22. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22(46):7155–7169. https://doi.org/10.1038/sj.onc.1206887

23. Jechlinger M, Sommer A, Morrigl R, Seither P, Kraut N, Capodieci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116(6):1561–1570. https://doi.org/10.1172/jci24654

24. Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985–2016. Breast 31:46–50. https://doi.org/10.1016/j.breast.2016.10.005

25. Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18(1):8. https://doi.org/10.1186/s13058-015-0665-1

26. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Can Res 62(13):3729–3735

27. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA (2008) Activation of PDGFC-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14(7):731–737. https://doi.org/10.1038/nm1787

28. Weitlaufers SA, Fredriksson L, Lawrence DA, Eriksson U (2016) Pharmacological targeting of the PDGF-CC signaling pathway for blood–brain barrier restoration in neurological disorders. Pharmacol Ther 167:108–119. https://doi.org/10.1016/j.pharmthera.2016.07.016

29. Kim HM, Jung WH, Koo JS (2015) Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. J Transl Med 13:222. https://doi.org/10.1186/s12967-015-0587-9

30. Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE (2001) Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 276(29):27406–27414. https://doi.org/10.1074/jbc.M101056200